Skip to main content
SpringerLink
Log in

Valsartan Orodispersible Tablets: Formulation, In vitro/In vivo Characterization

  • Research Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

Valsartan orodispersible tablets have been developed at 40-mg dose, with the intention of facilitating administration to patients experiencing problems with swallowing and hopefully, improving its poor oral bioavailability. Work started with selecting drug compatible excipients depending on differential scanning calorimetric analysis. A 33 full factorial design was adopted for the optimization of the tablets prepared by freeze-drying technique. The effects of the filler type, the binder type, and the binder concentration were studied. The different tablet formulas were characterized for their physical properties, weight variation, disintegration time, surface properties, wetting properties, and in vitro dissolution. Amongst the prepared 27 tablet formulas, formula number 6 (consisting of 4:6 valsartan:mannitol and 2% pectin) was selected to be tested in vivo. Oral bioavailability of two 40 mg valsartan orodispersible tablets was compared to the conventional commercial tablets after administration of a single dose to four healthy volunteers. Valsartan was monitored in plasma by high-performance liquid chromatography. The apparent rate of absorption of valsartan from the prepared tablets (C max = 2.879 μg/ml, t max = 1.08 h) was significantly higher than that of the conventional tablets (C max = 1.471 μg/ml, t max = 2.17 h), P ≤ 0.05. The relative bioavailability calculated as the ratio of mean total area under the plasma concentration–time curve for the orodispersible tablets relative to the conventional ones was 135%. The results of the in vivo study revealed that valsartan orodispersible tablets would be advantageous with regards to improved patient compliance, rapid onset of action, and increase in bioavailability.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Leidig M, Bambauer R, Kirchertz EJ, Szabã T, Handrock R, Leinung D, et al. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis. Clin Nephrol. 2008;69(6):425–32.

    CAS  PubMed  Google Scholar 

  2. Baumhäkel M, Müller U, Böhm M. Valsartan improves symptoms and quality of life in patients with chronic heart failure. MMW Fortschr Med. 2008;150 Suppl 1:48–53.

    PubMed  Google Scholar 

  3. Flynn JT, Meyers KE, Neto JP, De Paula Meneses R, Zurowska A, Bagga A, et al. Efficacy and safety of the angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. Hypertension. 2008;52(2):222–8.

    Google Scholar 

  4. Grahame-Smith DG, Aronson JK. Oxford textbook of clinical pharmacology and drug therapy, 3rd ed. Oxford University Press; 2002. p. 487–8.

  5. Parfitt K. Martindale, The complete drug reference. 32nd, Pharmaceutical Press; 1999. p. 960.

  6. Rizwan M, Aqil M, Ahad A, Sultana Y, Ali MM. Transderrmal delivery of valsartan: I. Effect of various terpenes. Drug Dev Ind Pharm. 2008;34(6):618–26.

    Article  CAS  PubMed  Google Scholar 

  7. European Pharmacopoeia; 4th ed., Suppl. 4.1. Council of Europe, Strasbourge, France; 2002. p. 2435.

  8. Pierre H, Matthias S, Rosa M. Fast disintegrating oral dosage form.US Patent 6,083,531; 1998.

  9. Gohel M, Patel M, Amin A, Agrawal R, Dave R, Bariya N. Formulation design and optimization of mouth dissolve tablets of nimesulide using vacuum drying technique. AAPS PharmSciTech. 2004;5(3):e36.

    Article  PubMed  Google Scholar 

  10. Habib W, Khankari R, Hontz J. Fast-dissolving drug delivery systems, critical review in therapeutics. Drug Carrier Systems. 2000;17(1):61–72.

    CAS  Google Scholar 

  11. Chang RK, Guo X, Burnside B, Couch R. Fast-dissolving tablets. Pharm Technol. 2000;24(6):52–8.

    CAS  Google Scholar 

  12. Clarke A, Brewer F, Johnson ES, Kelly EA. Proceeding of the 122nd Annual Meeting of the American Neurological Association, 1997, M69.

  13. Seager H. Drug-delivery products and the Zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998;50:375–82.

    CAS  PubMed  Google Scholar 

  14. Javadzadeh Y, Siahi-Shadbad MR, Barzegar-Jalali M, Nokhodchi A. Enhancement of dissolution rate of piroxicam using liquisolid compacts. I I Farmaco. 2005;60(4):361–5.

    Article  CAS  Google Scholar 

  15. Khan KA, Rhodes CT. Effect of compaction pressure on the dissolution efficiency of direct compression systems. Pharm Acta Helv. 1972;47:597–607.

    Google Scholar 

  16. Bi Y, Sunada H, Yonezawa Y, Danjo K, Otsuka A, Iida K. Preparation and evaluation of a compressed tablet rapidly disintegrating in the oral cavity. Chem Pharm Bull (Tokyo). 1996;44:2121–7.

    CAS  Google Scholar 

  17. Satana E, Altınay S, Göger NG, Özkan SA, Sentürk Z. J Pharm Biomed Anal. 2001;25(5–6):1009–13.

    Article  CAS  PubMed  Google Scholar 

  18. Corveleyn S, Remon JP. Formulation and production of rapidly disintegrating tablets by lyophilisation using hydrochlorothiazide as a model drug. Int J Pharm. 1997;152:215–25.

    Article  CAS  Google Scholar 

  19. Bolton S, Remington, the science and practice of pharmacy, 20th edition, Hanson, GR, Lippincott Williams; 2002. p.142.

  20. Thurmann PA. A novel anginotensin type1 receptor antagonist. Expert Opin Pharmacother. 2000;1(2):337–50.

    Article  CAS  PubMed  Google Scholar 

  21. Flesch G, Muller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Eur J Clin Pharmacol. 1997;52(2):115–20.

    Article  CAS  PubMed  Google Scholar 

  22. Daneshtalab N, Lewanczuk RZ, Jamali F. High-performance liquid chromatographic analysis of angiotensin II receptor antagonist valsartan using a liquid extraction method. J Chromatogr B. 2002;766:345–9.

    Article  CAS  Google Scholar 

  23. Macek J, Klima J, Ptacek P. Rapid determination of valsartan in human plasma by protein precipitation and high performance liquid chromatography. J Chromatogr B. 2006;832:169–72.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El Aini Street, Cairo, 11562, Egypt

    Howida Kamal Ibrahim & Doaa A. El-Setouhy

Authors
  1. Howida Kamal Ibrahim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Doaa A. El-Setouhy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Howida Kamal Ibrahim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ibrahim, H.K., El-Setouhy, D.A. Valsartan Orodispersible Tablets: Formulation, In vitro/In vivo Characterization. AAPS PharmSciTech 11, 189–196 (2010). https://doi.org/10.1208/s12249-009-9354-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-009-9354-7

Key words

Search

Navigation